Abstracts tagged "rheumatoid arthritis (RA) and risk"

Abstract Number: 1509 • 2015 ACR/ARHP Annual Meeting
Serum Nitrite Levels in Rheumatoid Arthritis and Relationship to Cardiovascular Risk Factors and Atherosclerosis Biomarkers
Kimberly P. Liang¹, Douglas P. Landsittel², Bernadette B. Sendon³, Donald M. Jones⁴, Rachel Gartland³, Suresh R. Mulukutla⁵, Steven E. Reis⁶, Flordeliza S. Villanueva⁵, Ali Hakim Shoushtari⁷, Cameron Dezfulian⁸ and Larry W. Moreland⁴, ¹Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Cardiology and Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, ⁷Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, ⁸Critical Care Medicine and Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Nitric oxide (NO) has been implicated in immune regulation, inflammation, arthritis and atherosclerosis. Raised levels of nitrite (NO2) in serum and synovial fluid have…
Abstract Number: 1550 • 2015 ACR/ARHP Annual Meeting
Flares of Disease Activity As Risk Factor for the Occurrence of Myocardial Infarction in Patients with Rheumatoid Arthritis
Esmee Bakker¹, Pauline Geuijen², Beata Radovits¹, Delia Popa-Diaconu¹, Calin Popa¹, Elke Arts¹, Alfons A. den Broeder³ and Jaap Fransen¹, ¹Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular diseases (CVD). The underlying mechanism is partly explained by the inflammation process in both…
Abstract Number: 1583 • 2015 ACR/ARHP Annual Meeting
Identifying Risk Factors for Progression of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Yashaar Chaichian¹, Dina Bassiri², Imre Noth³, Mary Strek³, Tammy Utset¹ and Rekha Vij³, ¹Medicine, Section of Rheumatology, University of Chicago Medical Center, Chicago, IL, ²Statistical & Applied Research, ACT, Inc., Iowa City, IA, ³Medicine, Section of Pulmonary/Critical Care, University of Chicago Medical Center, Chicago, IL
Background/Purpose: Interstitial lung disease (ILD) is recognized as a frequent extra-articular manifestation of rheumatoid arthritis (RA) associated with significant morbidity and mortality. Nevertheless, risk factors…
Abstract Number: 2019 • 2015 ACR/ARHP Annual Meeting
Serum Biomarkers of Inflammatory Arthritis in First Degree Relatives of Patients with Rheumatoid Arthritis and Their Association with Lifestyle Risk Factors
Jamie C Sergeant and RA-MAP Consortium, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose: Rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (anti-CCP) and C-reactive protein (CRP) are known serum biomarkers of inflammatory arthritis (IA) and have potential predictive…
Abstract Number: 2022 • 2015 ACR/ARHP Annual Meeting
Adherence to the Dietary Guidelines for Americans and Risk of Developing Rheumatoid Arthritis in Young and Middle-Aged Women
Yang Hu¹, Jeffrey A. Sparks², Karen H. Costenbader³, Frank Hu⁴, Elizabeth W. Karlson⁵ and Bing Lu⁵, ¹Nutrition, Harvard School of Public Health, Boston, MA, ²Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Harvard School of Public Health, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Little is known about the effect of adherence to the Dietary Guidelines for Americans on risk of developing rheumatoid arthritis (RA). The Alternative Healthy…
Abstract Number: 2023 • 2015 ACR/ARHP Annual Meeting
Breastfeeding, Oral Contraceptive and the Risk of Rheumatoid Arthritis: Results from the Swedish Epidemiological Investigation of RA Study
Cecilia Orellana¹, Lars Klareskog², Lars Alfredsson^3,4 and Camilla Bengtsson¹, ¹Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden, ²Department of Medicine, Karolinska University Hospital, Stockholm, Sweden, ³Karolinska Institute, Institute of Environmental Medicine, Stockholm, Sweden, ⁴Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Breastfeeding (BF) has been associated with both a decreased and an increased risk of developing rheumatoid arthritis (RA). Regarding oral contraceptive (OC) use and…
Abstract Number: 2104 • 2015 ACR/ARHP Annual Meeting
Influence on Treatment Decision Making of Providing Numerical Ranges of Side-Effect Risks
Nick Bansback^1,2, Mark Harrison³, William G Dixon⁴ and Paul Han⁵, ¹Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ²School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ³Centre for Health Evaluation and Outcomes Sciences, St Paul's Hospital, Vancouver, BC, Canada, ⁴Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵Center for Outcomes Research and Evaluation, Maine Medical Center, Portland, ME
Background/Purpose: Doctors and patients make treatment decisions after weighing benefits and harms. For harms, while people prefer treatments with smaller risks, how they react to…
Abstract Number: 1410 • 2014 ACR/ARHP Annual Meeting
Low Rates of Cardiovascular Risk Factor Modification Among High-Risk Rheumatoid Arthritis Patients: Barrier to Cardiovascular Prevention Strategies?
Kimberly P. Liang¹, Rohit Aggarwal², Juan (June) Feng³, Jason Lyons³, Heather Eng³, Stephen R. Wisniewski³, Melissa Saul⁴, Douglas P. Landsittel⁵, Douglas W. Chew¹, Aryan Aiyer⁶ and Larry W. Moreland⁷, ¹Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁴Biomedical Informatics, University of Pittsburgh, School of Medicine, Pittsburgh, PA, ⁵Medicine, Biostatistics and Clinical and Translational Science, University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, ⁶Department of Medicine, Division of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Despite higher risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA), systematic cardiovascular (CV) prevention strategies are lacking. Recent guidelines for CV risk…
Abstract Number: 1285 • 2014 ACR/ARHP Annual Meeting
Prevalence of Risk Factors for Gastrointestinal Side Effects of Drugs for the Treatment of Pain in Rheumatic Diseases and the Provision of Gastroprotective Treatment – Results of a Large Non-Intervention Study
Gustavo Citera¹, Edgardo Smecuol², Alberto Millán³, Manuel Robles⁴ and Ruben Mantilla⁵, ¹Universidad de Buenos Aires, Buenos Aires, Argentina, ²Hospital Municipal de Gastroenterología, Buenos Aires, Argentina, ³Hospital Universitario de Caracas, Caracas, Venezuela, ⁴Centro Médico Toluca, Toluca, Mexico, ⁵Clínica de Artritis y Rehabilitación (CAYRE), Bogota, Colombia
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are the long established first-line treatment for the management of pain associated with rheumatic diseases but carry a risk of…
Abstract Number: 825 • 2014 ACR/ARHP Annual Meeting
Serious Infections on TNF Inhibitors: Have the Risks Changed over Calendar Time, and How High Are They?
Elizabeth V. Arkema¹, Johan Askling² and the ARTIS Study group³, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institutet och Svensk Reumatologisk förening, Solna, Sweden
Background/Purpose: The rheumatoid arthritis (RA) population starting tumor necrosis factor inhibitors (TNFi) today is much different in terms of accumulated and concurrent disease activity and…
Abstract Number: 817 • 2014 ACR/ARHP Annual Meeting
Mortality in a Large Cohort of Patients with Early Rheumatoid Arthritis That Were Treated-to-Target for 10 Years
I.M. Markusse¹, L. Dirven², J.H. van Groenendael³, K.H. Han⁴, H.K Ronday⁵, P.J.S.M. Kerstens⁶, W.F. Lems^7,8, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Fransiscus Hospital, Roosendaal, Netherlands, ⁴Rheumatology, MCRZ hospital, Rotterdam, Netherlands, ⁵Rheumatology, Haga Hospital, The Hague, Netherlands, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Rheumatology, VU Medical Center, Amsterdam, Netherlands, ⁸Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: Recent studies showed diverging results about mortality trends in patients with rheumatoid arthritis (RA). Our aim was to determine survival after 10 years of…
Abstract Number: 2887 • 2014 ACR/ARHP Annual Meeting
Post-Menopausal Factors and the Risk of Seropositive and Seronegative Rheumatoid Arthritis Phenotypes: Results from the Nurses’ Health Study
Camilla Bengtsson¹, Susan Malspeis², Jeffrey A. Sparks³, Karen H. Costenbader³ and Elizabeth W. Karlson³, ¹The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Among women, the peak incidence of rheumatoid arthritis (RA) is reported to be 45-74 years of age. In addition, it has been suggested that…
Abstract Number: 2088 • 2014 ACR/ARHP Annual Meeting
Association of TNFAIP3 Gene Polymorphisms with the Risk for RA and Prediction of Therapy Outcome of TNFα-Blocker Treatment
Susanne Drynda¹, Marietta Gloetzner² and Joern Kekow¹, ¹Clinic of Rheumatology, Univ of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany, ²Univ of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany
Background/Purpose: The TNFα inducible protein 3 (TNFAIP3=A20) is an important regulatory protein for the inhibition of NFkB activation in TNFaR and TLR pathways. It belongs…
Abstract Number: 2018 • 2014 ACR/ARHP Annual Meeting
Do Mediterranean or Vegetarian Diets Influence Risk of Rheumatoid Arthritis?
Kari Johansson¹, Maria Sandberg², Saedis Saevarsdottir³, Martin Neovius¹, Lars Alfredsson², Johan Askling^1,3 and Camilla Bengtsson², ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Lifestyle factors are of major importance for development of RA. Yet, regarding the role of diet surprisingly little is known. The Mediterranean diet, rich…
Abstract Number: 1440 • 2014 ACR/ARHP Annual Meeting
Asymptomatic Carotid Plaques in RA Patients Are Associated with Increased HDL Function
Silvia Rollefstad¹, Bente Halvorsen², Tonje Skarpengland², Sella Provan³, Tore K. Kvien⁴ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose Reverse cholesterol transport (RCT) is a major anti atherogenic function of high density lipoprotein cholesterol (HDL) and has been shown to be related to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].